These are top 10 stocks traded on the Robinhood UK platform in July
On Thursday, RBC Capital Markets maintained a positive outlook on Veeva Systems (NYSE:VEEV) shares, with an analyst from the firm reiterating an Outperform rating and a $285.00 price target. The endorsement follows Veeva Systems’ solid performance in closing out the fiscal year, which saw the company’s shares rise 7% in after-hours trading. With analyst targets ranging from $201 to $320 and a market capitalization of $35.7 billion, Veeva maintains strong financial metrics, including a healthy gross profit margin of 74.5%.
Veeva Systems, known for its cloud-based software for the global life sciences industry, reported subscription growth and healthy billings that aligned with consensus expectations. The company’s guidance for FY26 exceeded consensus, driven by an uptick in profitability and sustained strength in subscription services. InvestingPro analysis reveals the company holds more cash than debt and maintains excellent liquidity, with current assets significantly exceeding short-term obligations.
The firm’s analysis highlighted Veeva’s successful execution throughout the year, particularly in Commercial and Vault CRM migration, which positions the company well for the upcoming year. The analyst noted that Veeva’s Clinical platform continues to be regarded as best in class, with the potential for suite expansion capabilities to drive further growth and profitability. Discover more insights about Veeva’s growth potential in the comprehensive Pro Research Report, available exclusively on InvestingPro, along with 10+ additional ProTips and detailed financial metrics.
The positive assessment by RBC Capital Markets underscores Veeva Systems’ robust performance and strategic initiatives that appear to set a strong foundation for continued success in the next fiscal year. The company’s focus on expanding its suite and strengthening its Clinical platform is expected to contribute to its growth trajectory and profitability, supported by its impressive revenue growth of 16.2% and strong return on equity of 14%.
In other recent news, Veeva Systems reported robust financial results for the fourth quarter of fiscal year 2025, with revenue reaching $721 million, surpassing the forecast of $699.18 million. Earnings per share also exceeded expectations at $1.74 compared to the projected $1.58. Evercore ISI raised its price target for Veeva Systems to $250, citing the company’s impressive financial performance and strong profitability. Truist Securities also lifted its price target to $217, acknowledging Veeva’s better-than-expected earnings and future guidance. Meanwhile, Raymond (NSE:RYMD) James adjusted its price target to $285, maintaining an Outperform rating and highlighting Veeva’s expanding product suite and market influence.
Veeva Systems provided guidance for fiscal year 2026 that was ahead of market consensus once adjusted for foreign exchange impacts. The company added 20 new customers to its Vault CRM platform, predominantly smaller companies selecting their first CRM system. Management confirmed that a top 20 biopharma company is on schedule with its migration to Vault CRM in 2025, with expectations to secure multiple new contracts with top 20 biopharma companies. Despite foreign exchange headwinds anticipated to impact annual revenue by approximately $20 million, Veeva’s operating margins for FY26 are expected to remain strong at around 43%.
Analysts from Evercore ISI and Truist Securities noted Veeva Systems’ confidence in securing and retaining a large majority of top 20 CRM customers. The company’s focus on innovation, such as the introduction of AI-driven products like Veeva Pulse, positions it well against competitors. Veeva Systems’ overall performance and strategic initiatives have led to positive adjustments in price targets by several analyst firms, reflecting recognition of the company’s recent achievements and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.